The U.S. Patent Office tribunal has rejected challenges to two key patents owned by Novo Nordisk, which cover the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic.…
US Patent Office won’t review two Novo Nordisk patents for Wegovy, Ozempic
By News Team October 2, 2023